Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 25Myelodysplastic Syndromes 4Recurrence 2Leukemia, Myeloid 2Hematologic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Targeted Therapy 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Blast Crisis 1

Interventions

Cyclophosphamide 31fludarabine 28Whole-Body Irradiation 18Mycophenolic Acid 18venetoclax 14Tacrolimus 14fludarabine phosphate 13Standard of Care 13Specimen Handling 10Practice Guidelines as Topic 10Melphalan 10Busulfan 10Sirolimus 9Thiotepa 8Interviews as Topic 8Azacitidine 8Educational Status 7trametinib 6Surveys and Questionnaires 6Methods 6Mesna 6Biopsy 6thymoglobulin 5Rituximab 5Magnetic Resonance Spectroscopy 5Filgrastim 5Early Intervention, Educational 5Behavior Therapy 5Antilymphocyte Serum 5Peripheral Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematologic Neoplasms × gilteritinib × 1 year × Clear all
NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06992934 2025-08-03

TARGETALLO

Centre Hospitalier Universitaire de Nice

Phase NA Not yet recruiting
10 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡